Zepp Health Corporation
ZEPP · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.35 | 0.01 | 0.00 | -0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 253.92 | -21.55 | -5.21 | -4.45 |
| Quality | ||||
| ROIC | -0.26% | -1.45% | -4.36% | -2.03% |
| Gross Margin | 38.16% | 36.18% | 37.27% | 36.83% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -17.17% | -26.40% | -31.48% | -31.93% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 53.61 | -19.46 | -4.57 | -3.88 |
| Interest Coverage | -0.77 | -4.90 | -13.53 | -6.18 |
| Efficiency | ||||
| Inventory Turnover | 0.53 | 0.48 | 0.38 | 0.66 |
| Cash Conversion Cycle | -121.99 | 96.96 | 142.20 | 133.78 |